Alnylam Pharmaceuticals Put Buyers Take Profits During Slide

Sanofi divested its 10% stake in Alnylam Pharm

May 3, 2019 at 1:49 PM
facebook twitter linkedin

Amid an up day in the broader equities market, the shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) are trading 6.4% lower at $77.25, on news Sanofi (SNY) divested its roughly 10% stake in the biopharmaceutical firm. This comes after the two companies concluded a research and options phase of an RNAi therapeutics collaboration that began in 2014.

It's already been a rough week for ALNY stock -- down 11.3% so far -- which has been falling since the company's Wednesday-morning earnings report. The shares are now poised to close below their 120-day moving average for the first time since late February, but could be finding a familiar foothold in the $77-$78 range, site of an early January bull gap that served as a floor in the first quarter.

alny stock daily price chart on may 3

ALNY options traders are in overdrive this afternoon, with 3,000 puts and 2,035 calls on the tape -- five times the average daily volume of 981 contracts, and total volume pacing in the 99th annual percentile. Options bears may be taking profits at the May 90 put. Trade-Alert indicates a number of these puts were bought to open on Monday, April 30, for around $4.65 apiece, and the bid price at this now in-the-money strike was last seen at $12.30.

Elsewhere on Wall Street, short sellers have been ramping up their bearish exposure to the biopharma. Short interest edged up 3.1% in the most recent reporting period to 5.52 million shares. This accounts for a healthy 6.1% of Alnylam Pharm's available float, or 7.7 times the average daily pace of trading.

Analysts, meanwhile, are mostly bullish on the ALNY stock. While 10 of 13 covering brokerages maintain a "buy" or better rating, the average 12-month price target of $125.22 is a roughly 62% premium to current trading levels.


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial


Special Offers from Schaeffer's Trading Partners